- About us
- Clinical trials
- News & Publications
SOTIO posters from SITC 2021
Posters on IL-15 superagonist SO-C101 (SOT101) will be available here on the date of presentation at SITC 2021.
WE WANT TO HAVE A SAY IN THINGS
“Out of the approximately 400 programs we analyze annually, only one or two result in a successfully completed transaction,” says Radek Špíšek, CEO of the biotechnology company Sotio.
Three years ago, Radek Špíšek said that he had a hard time falling asleep, knowing how much money Petr Kellner spends on Sotio. Kellner, the wealthiest Czech and the founder of the PPF business empire, established the biotechnology company 10 years ago, aiming to eventually develop a proprietary cancer treatment. The person to do that was to be none other than Radek Špíšek, who was at that time working as an immunotherapy specialist in the Motol Hospital. His bad dreams are now over. Shortly before the end of last year, Sotio managed to close a highly profitable deal, albeit in the investment field. “Our biggest dream still is that Sotio will become a pharmaceutical company,” stresses Špíšek.